Skip to main content
Premium Trial:

Request an Annual Quote

Gene Synthesis Proligo Rules DNA Bases Lock, Stock, and Barrel

Premium

It’s still a fairly small and young company, but Proligo, with joint offices in Hamburg, Germany, and Boulder, Colo., has already declared itself indispensable in the genomics arena. With key patents in DNA synthesis, the company is a virtual gatekeeper for people looking to make primers or any other strings of As, Cs, Ts, and Gs. “We manufacture those monomers … at a multi-ton level,” says Wolfgang Pieken, president and CEO.

Pieken founded the company in 1998 as a NeXstar Technology spinout, and German firm Degussa acquired it as a subsidiary last August. Though much of Proligo’s business comes from its nucleic-acid supply line, DNA synthesis, and DNA ingredient production — particularly ribosomes and aptamers — Pieken is more enthusiastic about his new product line using proprietary locked nucleic acid, or LNA, technology that implements modified versions of each base.

“Most of the time [in DNA studies], you’re trying to discriminate, in a sequence of about 20, a single letter mismatch,” Pieken says. “If you think about native DNA, it’s really not ideally suited for such discrimination events. It’s made to perform evolution, where a certain degree of sloppiness, if you want, is a desired effect.” The Proligo solution: adding a locked monomer to a DNA sequence for confirmation use. “For each single LNA monomer incorporation, you increase the binding strength by three to five degrees Centigrade,” Pieken says. It also helps level out binding specificity on DNA chips with many sequences that have different optimal binding temperatures — making genotyping an early target application.

— Meredith Salisbury

 

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.